WaferGen Announces Third Quarter 2008 Financi... (target markets including from companiest...)

WaferGen Announces Third Quarter 2008 Financial Results

Date:11/10/2008

target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2007, and its subsequent Quarterly Reports on Form 10-Q filed with the SEC. Investors and security holders are urged to read this document free of charge on the SEC's web site at http://www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:

Vida Communication (on behalf of WaferGen)

Stephanie Diaz (investors) Tim Brons (media)

415-675-7400 415-675-7400

sdiaz@vidacommunication.com tbrons@vidacommunication.com

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

(A Development Stage Company)

Condensed Consolidated Statements of Operations (Unaudited)

September 30, December 31,

2008 2007

Assets

Current assets:

Cash and cash equivalents $3,209,394 $5,189,858

Accounts receivables 227,616 139,827

Inventories 158,195 62,521

Prepaid expenses and

other current assets 141,965 87,487

Total current assets
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. WaferGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
3. WaferGen to Present at the Seventh Annual BIO Investor Forum
4. WaferGen Announces Second Quarter 2008 Financial Results
5. WaferGen to Present at the Ninth Annual Beyond Genome Conference
6. WaferGen Announces Signing of Two Private Placements
7. WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference
8. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
9. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
10. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
11. WaferGen Announces Management Team Promotions

Post Your Comments:

(Date:12/16/2009)... Dec. 16 Martek Biosciences Corporation (Nasdaq: ... fourth quarter and fiscal year ended October 31, 2009. ... 3% from $90.4 million in the fourth quarter of ... per diluted share, for the fourth quarter of fiscal ... $0.31 per diluted share, in last year,s fourth quarter. ...

(Date:12/16/2009)... Hahnemann among the Best in the Nation ... Hospital proudly announces it has been granted Magnet(R) ... Magnet Recognition Program(R). Magnet(R) is one of the ... center can achieve, and places Hahnemann among the ... have achieved this prestigious distinction. ,, At 9:00 ...

(Date:12/16/2009)... VEGAS, Dec. 16 Cord Blood America, ... blood stem cell preservation company ( http://www.cordblood-america.com ... of stem cells, a biological insurance policy, to ... has reduced its debt by a total of ... of 2009 and total debt eliminated for the ...

(Date:12/16/2009)... WALTHAM, Mass., Dec. 16 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... Biotech/Janssen-Cilag,s Stelara and Abbott,s briakinumab (both interleukin inhibitors) ... in 2012 in the drug market for moderate ... will experience greater uptake, capturing nearly three times ...

[0] Martek Announces Fourth Quarter and FY 2009 Financial Results [0] Hahnemann University Hospital Granted Magnet(R) Status [0] Cord Blood America Says 2009 Debt Reduction Tops $10 Million [0] In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market

... S*BIO Pte Ltd, a cancer therapeutics,company, today announced ... led by Bio*One Capital and new investor Aravis ... Fund advised by,Adamant Biomedical Investments AG and Zurcher ... fund the development efforts of its,two lead compounds, ...

... SYDNEY, Australia, Oct. 19 /Xinhua-PRNewswire-FirstCall/ --,Pharmaceutical company ... it had received approval to market Aridol ... Aridol is indicated for measuring airway hyperresponsiveness ... countries - Denmark, Finland, France, Germany,Greece, Ireland, ...

... Mattel Children,s Hospital UCLA today announced the launch ... explore the future of personalized medicine for children, ... is one of the world,s first dedicated solely ... , "Why develop a nanopediatrics program? Because children ...

Other Biology Technology:S*BIO Completes US$26 Million Equity Financing 2 S*BIO Completes US$26 Million Equity Financing 3 S*BIO Completes US$26 Million Equity Financing 4 Pharmaxis Aridol Approved for Sale in Switzerland 2 Mattel Children's Hospital UCLA launches program in nanopediatrics 2

S*BIO Completes US$26 Million Equity Financing Pharmaxis Aridol Approved for Sale in Switzerland Mattel Children's Hospital UCLA launches program in nanopediatrics

(Date:12/16/2009)... Va., Dec. 9 CSC (NYSE: ... the American Association for Laboratory Accreditation awarded ... (ISO/IEC) 17025:2005 accreditation to the company,s Test ... Identity Labs located in Fairmont, W.Va. The ... laboratory in the world to achieve this ...

(Date:12/15/2009)... The 2009 Frost & Sullivan European Border ... Sagem Securite (Safran Group) for its innovative ... the company,s expertise in advanced biometric technology ... value-added products to end users. ,, ... Securite has been involved in delivering identification ...

(Date:12/15/2009)... When treating devastating brain diseases such as Alzheimer,s ... to find something to help a patient. , But ... the vast majority of patients with ataxia disabling ... , University of Florida neurologists are trying to change ... grant from the National Institute of Neurological Disorders and ...

[0] CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation [0] Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems [0] UF to lead national effort to help patients with rare brain disease

... Vegetables , Protozoa found on lettuce and ... to their survival on produce surfaces say researchers ... Safety and Microbiology Research Unit, Albany, California. ... issue of the journal Applied and Environmental Microbiology. ...

... Papers presented at the 1st European Lung Cancer Conference, ... (ESMO) and the International Association for the Study of ... that common viruses may contribute to the development of ... by far the most important factor that contributes to ...

... The vaccinia virus has a problem: it is a giant ... infiltrate a cell and reproduce. Professor Ari Helenius and Postdoc ... discovered what this strategy is. In the process, they stumbled ... , In order to infiltrate a cell, the ...

Other Biology News:Tips from the Journals of the American Society for Microbiology 2 Tips from the Journals of the American Society for Microbiology 3 Tips from the Journals of the American Society for Microbiology 4 Viruses may play a role in lung cancer development 2 A step forward in virology 2 A step forward in virology 3

Tips from the Journals of the American Society for Microbiology Viruses may play a role in lung cancer development A step forward in virology

... Technology's family of light scattering instruments. The ... chromatograph and enables you to get multi-angle ... HTmD is easily installed in the oven ... 2000 device and enables you to get ...

...

... White solid. PROTECT FROM LIGHT. PACKAGED ... compound that acts as a selective, ... PTP1B (IC 50 = 4 ... 403 and PTP1B 298 , ...

... White walled plates enhance luminescent signals ... fluorescence,• Not treated (or medium binding) ... and binds biomolecules through passive interactions,• ... of large molecules, such as antibodies, ...

Biology Products:

High Temperature miniDAWN (HTmD) for 150C, PL220C, Alliance 2000 from Wyatt Technology Sf21 Insect Cells from BD Biosciences Pharmingen PTP1B Inhibitor from Calbiochem CORNING 1536 WELL PLATE,2UL,WHITE,NON-TREATED,NON STERILE from Sigma-Aldrich

WaferGen Announces Third Quarter 2008 Financi...(target markets including from companiest...)